Treatment-related adverse events reported in ≥10% of patients randomized to enasidenib or CCR (safety population)
| Category . | Enasidenib . | CCR . |
|---|---|---|
| Preferred term . | (n = 157) . | (n = 141) . |
| Any treatment-related adverse event, n (%) | 121 (77.1) | 86 (61.0) |
| Nausea | 35 (22.3) | 22 (15.6) |
| Blood bilirubin increased | 31 (19.7) | 1 (0.7) |
| Thrombocytopenia | 24 (15.3) | 15 (10.6) |
| Decreased appetite | 23 (14.6) | 5 (3.5) |
| Differentiation syndrome | 22 (14.0) | 0 |
| Vomiting | 20 (12.7) | 8 (5.7) |
| Neutropenia | 13 (8.3) | 17 (12.1) |
| Febrile neutropenia | 4 (2.5) | 17 (12.1) |
| Category . | Enasidenib . | CCR . |
|---|---|---|
| Preferred term . | (n = 157) . | (n = 141) . |
| Any treatment-related adverse event, n (%) | 121 (77.1) | 86 (61.0) |
| Nausea | 35 (22.3) | 22 (15.6) |
| Blood bilirubin increased | 31 (19.7) | 1 (0.7) |
| Thrombocytopenia | 24 (15.3) | 15 (10.6) |
| Decreased appetite | 23 (14.6) | 5 (3.5) |
| Differentiation syndrome | 22 (14.0) | 0 |
| Vomiting | 20 (12.7) | 8 (5.7) |
| Neutropenia | 13 (8.3) | 17 (12.1) |
| Febrile neutropenia | 4 (2.5) | 17 (12.1) |
CCR, conventional care regimen.